Blurbs

Analysts Conflicted on These Healthcare Names: Adicet Bio (ACET) and Terns Pharmaceuticals (TERN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adicet Bio (ACETResearch Report) and Terns Pharmaceuticals (TERNResearch Report).

Adicet Bio (ACET)

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Adicet Bio today and set a price target of $21.00. The company’s shares closed last Thursday at $20.78, close to its 52-week high of $21.21.

According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of -9.4% and a 34.5% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Adicet Bio has an analyst consensus of Strong Buy, with a price target consensus of $27.40, implying a 31.9% upside from current levels. In a report issued on November 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.

See the top stocks recommended by analysts >>

Terns Pharmaceuticals (TERN)

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Terns Pharmaceuticals, with a price target of $6.00. The company’s shares closed last Thursday at $4.85.

According to TipRanks.com, Arce is a 3-star analyst with an average return of 3.1% and a 34.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Terns Pharmaceuticals with a $7.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACET:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More